Navigating life with Retinitis Pigmentosa (RP) brings unique challenges, but for Charles-Edouard Catherine, these challenges have only strengthened his resolve to thrive and help others do the same. RP is a rare, inherited disorder that causes progressive vision loss due to the gradual breakdown […]
Living with Parkinson’s disease is a reality that many can scarcely imagine. The journey of navigating life with this progressive neurological disorder profoundly impacts the quality of life for patients and loved ones. Notable figures like Michael J. Fox have used their platforms to […]
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating individuals living with Parkinson’s disease At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high […]
OpCT-001 is the first iPSC-derived investigational cell therapy to be clinically tested for treating primary photoreceptor diseases Primary photoreceptor diseases are a subgroup of inherited retinal disorders that affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision […]
Regenerative Medicine Advanced Therapy (RMAT) designation follows phase I clinical trial results demonstrating that bemdaneprocel is well tolerated with no major safety issues through 18 months Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s […]
Collaboration will add a new multigene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness CAMBRIDGE, MA USA and COLUMBIA, MD, March […]
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months After stopping the 12-month immune suppression regimen, assessment of 18-month data shows evidence of sustained cell engraftment […]
First iPSC therapy candidate to be licensed from the strategic R&D collaboration forged between BlueRock, FUJIFILM Cellular Dynamics, and Opsis Therapeutics in 2021 Primary photoreceptor diseases affect the structure and function of the photoreceptor cells in the retina, leading to irreversible vision loss in […]
This press release was updated on October 2, 2023. Specifically, two data points have been updated after it was discovered that the data point from the Hauser diary OFF time in the low dose cohort and the data point from the MDS-UPDRS Part III low […]
Research collaboration leverages bit.bio’s machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio’s […]
